SNSS News and Press, Viracta Therapeutics Inc Com From 07/07/20

With a goal of sharpening its focus on candidate SNS-510, Sunesis Pharmaceuticals (NASDAQ: SNSS ) announces a workforce reduction of about 30%. The downsizing should be completed this quarter and will extend its cash runway into Q2 2021. More news on: Sunesis Pharmaceuticals, Inc., Taked...

SOUTH SAN FRANCISCO, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a reduction in workforce of approximately 30% of its head count to focus on development of its first-in-class PDK1 inhibitor SNS-510. The reduction in workforc...

Sunesis Pharmaceuticals (NASDAQ: SNSS ) slumps  45%  premarket on the heels of the announcement that it will not advance its non-covalent BTK inhibitor vecabrutinib into the planned Phase 2 portion of the Phase 1b/2 trial in adults with relapsed/refractory chronic lymphocytic leu...

SOUTH SAN FRANCISCO, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the Company will not advance its non-covalent BTK inhibitor vecabrutinib into the planned Phase 2 portion of the Phase 1b/2 trial in adults with relapsed/ref...

These Penny Stocks Take Aim At New June Highs When you look at the stock market today and analyze some of the top penny stocks , do you find certain things in common? Honestly, if you can’t answer that question, you’re not alone. Penny stocks tend to be their own “thing...

Sunesis Pharmaceuticals, Inc. (SNSS) Q1 2020 Earnings Conference Call May 7, 2020 4:30 PM ET Company Participants Par Hyare - Investor Relations Dayton Misfeldt - Interim Chief Executive Officer Judy Fox - Chief Scientific Officer, Executive Vice President, Research & Devel...

Sunesis Pharmaceuticals (NASDAQ: SNSS ): Q1 GAAP EPS of -$0.05 beats by $0.02 . More news on: Sunesis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SOUTH SAN FRANCISCO, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the first quarter ended March 31, 2020. Loss from operations for the three months ended March 31, 2020 was $5.8 million. As of&...

SOUTH SAN FRANCISCO, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Thursday, May 7 th , 2020 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the first quarter en...

Menlo Therapeutics (NASDAQ: MNLO ) initiated with Buy rating and $8 (113% upside) price target at Bank of America. More news on: Menlo Therapeutics Inc., Nutrien Ltd., Apellis Pharmaceuticals, Inc., Healthcare stocks news, , Stocks on the move, Read more ...